Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
2.
J Pediatr Hematol Oncol ; 45(7): e847-e856, 2023 Oct 01.
Artigo em Inglês | MEDLINE | ID: mdl-37539995

RESUMO

OBJECTIVE: The aim of this study was to quantify and describe baseline patient and parent-proxy health-related quality of life scores in patients with low-flow vascular malformations at a single, tertiary-care vascular anomalies clinic. STUDY DESIGN: This is a retrospective study of data collected on patients with low-flow vascular malformations between the ages of 2 to 25 who were seen at a single, tertiary-care center vascular anomalies clinic. A total of 266 patients are included in this study. RESULTS: Patients with lymphatic malformations report decreased quality of life scores as compared with venous malformations in the emotional, psychological, school, and social domains. Patients with lower extremity malformation report decreased quality of life scores as compared with head/neck, trunk, upper extremity, and multifocal malformations; most notably in the physical domain. CONCLUSIONS: Treatment of low-flow vascular malformations should aim to improve patient quality of life. The use of standardized health-related quality of life measures in this study quantifies baseline quality of life scores among patients with low-flow vascular malformations.

3.
Pediatr Blood Cancer ; 69 Suppl 3: e28863, 2022 08.
Artigo em Inglês | MEDLINE | ID: mdl-36070214

RESUMO

The care of patients with vascular anomalies is quickly becoming a complex field requiring high-quality, coordinated multidisciplinary care. In this article, we review the history of multidisciplinary care in this field, discuss the benefits of this model of care, and outline some of the essential components and structure of a successful vascular anomalies team. We provide an overview of two example programs and a roadmap for other centers to develop their own multidisciplinary vascular anomalies teams.


Assuntos
Doenças Vasculares , Malformações Vasculares , Humanos , Malformações Vasculares/terapia
4.
Pediatr Blood Cancer ; 69(5): e29610, 2022 05.
Artigo em Inglês | MEDLINE | ID: mdl-35234344

RESUMO

BACKGROUND: Congenital venous malformations (VMs) are low-flow vascular anomalies that can cause coagulation abnormalities. This phenomenon, referred to as localized intravascular coagulopathy (LIC), is characterized by elevated D-dimer, hypofibrinogenemia, and/or thrombocytopenia. Increased risk for LIC includes patients with an extensive VM, multifocal VM, and Klippel-Trenaunay and CLOVES syndromes. Peri-procedural anticoagulation has been given to prevent complications from LIC in patients undergoing surgical/interventional procedures; however, the rate of clinically relevant complications from sclerotherapy is largely unknown. The purpose of this study is to describe a single-institution's incidence of LIC in patients with VMs and coagulopathy-related complications following sclerotherapy. DESIGN/METHODS: Retrospective chart review of patients, 0-21 years of age, with VM who underwent sclerotherapy without peri-procedural anticoagulation and had coagulation profiles evaluated within 1 month prior to sclerotherapy. DATA COLLECTED: diagnosis type (high vs. low risk for LIC), coagulation profile (including PT/PTT, D-dimer, fibrinogen, and platelet count), sclerosant used, and post-procedure outcomes. Coagulopathy-related complications included clinically relevant bleeding, deep vein thrombosis (DVT), and pulmonary embolism (PE). RESULTS: N = 138 patients; 59.4% were female. The most common location of VM was the lower extremity (47.8%; 66/138). Of patients with high-risk VMs (29/138 [21%]), 11/29 (37.9%) had laboratory values consistent with LIC, whereas 5% (5/109) of low-risk VMs had LIC. In sum, 492 sclerotherapy procedures were performed with no complications of bleeding, DVT, or PE. CONCLUSION: Patients undergoing sclerotherapy for VM with abnormal coagulation profiles may not require peri-procedural low molecular weight heparin (LMWH). Further studies are needed to precisely define which patients would benefit from anticoagulation.


Assuntos
Transtornos da Coagulação Sanguínea , Embolia Pulmonar , Malformações Vasculares , Anticoagulantes , Transtornos da Coagulação Sanguínea/etiologia , Transtornos da Coagulação Sanguínea/terapia , Feminino , Heparina de Baixo Peso Molecular , Humanos , Masculino , Estudos Retrospectivos , Escleroterapia/efeitos adversos , Malformações Vasculares/terapia
5.
Radiographics ; 39(2): 491-515, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-30844349

RESUMO

Congenital limb length discrepancy disorders are frequently associated with a variety of vascular anomalies and have unique genetic and phenotypic features. Many of these syndromes have been linked to sporadic somatic mosaicism involving mutations of the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway, which has an important role in tissue growth and angiogenesis. Radiologists who are aware of congenital limb length discrepancies can make specific diagnoses based on imaging findings. Although genetic confirmation is necessary for a definitive diagnosis, the radiologist serves as a central figure in the identification and treatment of these disorders. The clinical presentations, diagnostic and imaging workups, and treatment options available for patients with Klippel-Trenaunay syndrome, CLOVES (congenital lipomatous overgrowth, vascular anomalies, epidermal nevi, and scoliosis/spinal deformities) syndrome, fibroadipose vascular anomaly, phosphatase and tensin homolog mutation spectrum, Parkes-Weber syndrome, and Proteus syndrome are reviewed. ©RSNA, 2019.


Assuntos
Anormalidades Múltiplas/diagnóstico por imagem , Deformidades Congênitas dos Membros/diagnóstico por imagem , Extremidade Inferior/diagnóstico por imagem , Malformações Vasculares/diagnóstico por imagem , Feminino , Humanos , Síndrome de Klippel-Trenaunay-Weber/diagnóstico por imagem , Lipoma/diagnóstico por imagem , Masculino , Anormalidades Musculoesqueléticas/diagnóstico por imagem , Nevo/diagnóstico por imagem , Síndrome de Proteu/diagnóstico por imagem , Síndrome de Sturge-Weber/diagnóstico por imagem , Síndrome
6.
Pediatr Dev Pathol ; 21(1): 95-99, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-29187030

RESUMO

Hemophagocytic Lymphohistiocytosis (HLH) is a hyperinflammatory disorder that may be encountered as a primary or secondary phenomenon. HLH secondary to lymphoma has been described, more frequently in adults than in children. T-cell/Histiocyte-rich B-cell lymphoma (THRLBCL) is a large B-cell lymphoma that resides in a microenvironment of robust host immune response and has previously been associated with HLH in adults. Here, we describe the first case of HLH secondary to THRLBCL in an adolescent patient.


Assuntos
Histiócitos/metabolismo , Linfo-Histiocitose Hemofagocítica/etiologia , Linfoma Difuso de Grandes Células B/diagnóstico , Linfócitos T/metabolismo , Adolescente , Biomarcadores/metabolismo , Humanos , Linfo-Histiocitose Hemofagocítica/diagnóstico , Linfoma Difuso de Grandes Células B/complicações , Linfoma Difuso de Grandes Células B/metabolismo , Linfoma Difuso de Grandes Células B/patologia , Masculino
7.
Pediatr Blood Cancer ; 50(5): 1054-5, 2008 May.
Artigo em Inglês | MEDLINE | ID: mdl-17973317

RESUMO

The role of radiation therapy for those with leukemia cutis, particularly pediatric patients, remains unclear. This report describes the first two cases of disseminated leukemia cutis in adolescents treated with total skin electron beam therapy. Both patients had resolution of their skin disease and significant palliation of symptoms. Total skin electron irradiation is an option for adolescents suffering from significant extramedullary leukemia involving the skin. While it is uncertain if this treatment has any improvement in disease-free survival, the benefits of total skin electron therapy for symptom palliation should be considered.


Assuntos
Leucemia Monocítica Aguda/radioterapia , Radioterapia de Alta Energia , Neoplasias Cutâneas/radioterapia , Tomografia Computadorizada por Raios X , Adolescente , Adulto , Humanos , Leucemia Monocítica Aguda/patologia , Masculino , Dosagem Radioterapêutica , Neoplasias Cutâneas/patologia
8.
Curr Hematol Rep ; 2(6): 522-7, 2003 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-14561398

RESUMO

Neutrophils are the immune system's main cellular defense against bacterial and fungal infections. Transfusion of granulocytes has been considered a therapeutic modality for severe bacterial and fungal infections in patients with prolonged neutropenia and with functional neutrophil disorders. Good theoretic and experimental evidence demonstrating granulocyte transfusion efficacy exists in preventing and treating severe infection. However, clinical evidence has been more difficult to interpret, with efficacy equivocal in many studies and further trials hindered by limitations in collecting adequate doses of leukocytes from healthy steroid-mobilized donors. The development and use of granulocyte colony-stimulating factor to stimulate normal donors has generated renewed interest in granulocyte transfusions. In clinical studies, granulocyte colony-stimulating factor has markedly enhanced the yield of leukocytes collected from normal donors, which may improve clinical outcomes in patients with severe infections and neutropenia who receive granulocyte transfusions. Preliminary clinical evidence, when correct granulocyte dose per patient body weight is optimized, suggests efficacy. However, well-designed randomized clinical trials are necessary to definitively establish granulocyte transfusions as a viable therapeutic modality in the treatment of severe bacterial and fungal infections in patients with functional neutrophil disorders or neutropenia.


Assuntos
Granulócitos/transplante , Transfusão de Leucócitos , Doadores de Sangue , Preservação de Sangue , Separação Celular , Dexametasona/administração & dosagem , Fator Estimulador de Colônias de Granulócitos/administração & dosagem , Granulócitos/efeitos dos fármacos , Doença Granulomatosa Crônica/terapia , Humanos , Recém-Nascido , Neutropenia/terapia , Prednisona/administração & dosagem , Proteínas Recombinantes , Sepse/terapia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA